Lacerta Therapeutics jobs and careers
Alachua, FL, United States
About Lacerta Therapeutics
Lacerta Therapeutics is a clinical stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and lysosomal storage diseases. With unmatched scientific expertise and depth in the development, production, and application of AAV vectors, LacertaTherapeutics is advancing its clinical programs using its proprietary capsid variants and scalable vector manufacturing platform. The experience and accomplishments of the Lacerta Therapeutics founders are unsurpassed in AAV gene therapy. In addition to world-class basic AAV vector development and gene therapy clinical trial expertise, our team brings to bear individuals with novel insight into developing novel, targeted neurological and lysosomal storage disease treatments.
Founded in 2017 by Arun Srivastava, Coy Heldermon, Edgar Rodriguez-Lebron, Kenneth Warrington, Nicholas Muzyczka, Ronald Mandel, Sergei Zolotukhin and Todd E. Golde.
- Founded
- 2017
- Employees
- 125
- Total funding
- $30M
- Headquarters
- Alachua
Leadership
The top of Lacerta Therapeutics's org chart, with how many people report into each leader.
Barb Eppler
VP, Quality
Venu Talla
Director Capsid Engineering
John Spence
Senior Principal Scientist
Megha Mahabole, MS, CTBS
Senior Scientist
Ryan M Spengler
Assistant Director, Bioinformatic Sciences
Shannon Wilson
Director of Finance
April Green
Principal Scientist
Fatima Shaerzadeh
Principal Scientist
Board
Jackson Streeter
Chairman
Nicholas Muzyczka
Advisor
Marc Woldff
Director
Coy Heldermon
Director
Arun Srivastava
Advisor
Joseph Zenkus
Director
Jobs at Lacerta Therapeutics
No open positions right now. Explore more companies on TheJobsMap.